Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Susana Maria Campos, M.D.

Co-Author

This page shows the publications co-authored by Susana Campos and Stephen Cannistra.
Connection Strength

0.372
  1. Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.
    View in: PubMed
    Score: 0.140
  2. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
    View in: PubMed
    Score: 0.120
  3. Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
    View in: PubMed
    Score: 0.059
  4. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
    View in: PubMed
    Score: 0.030
  5. Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.